サンプル依頼リスト カート
  • English
  • Korean
表紙：巣状分節性糸球体硬化症治療薬の世界市場レポート 2024年
市場調査レポート
商品コード
1415613

巣状分節性糸球体硬化症治療薬の世界市場レポート 2024年

Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
巣状分節性糸球体硬化症治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

巣状分節性糸球体硬化症治療薬市場規模は近年力強く成長しています。2023年の144億3,000万米ドルから2024年には157億7,000万米ドルに、CAGR9.3％で拡大します。実績期間の成長は、疾患有病率の増加、新しい治療法に対する需要の増加、製薬部門からの関心の高まり、政府支援の増加に起因しています。

巣状分節性糸球体硬化症（FSGS）治療薬市場の成長は、ヘルスケア支出の増加によって促進されると予想されます。ヘルスケア支出は、特定のヘルスケアシステムや経済圏において、特定期間中にヘルスケアサービスや関連製品、活動に投資された金額の総額を包括しています。ヘルスケア支出の増加は、巣状分節性糸球体硬化症（FSGS）治療薬の開発と利用可能性において重要な役割を果たしています。医療費の増加は、研究費の増加や臨床試験の増加につながり、最終的には薬剤開発の改善に寄与します。例えば、英国国家統計局の報告によると、英国のヘルスケア支出は2020年から2021年にかけて名目で9.4％、実質で9.7％増加することが明らかになった。2021年の英国の総医療費は3,672億5,000万米ドル（2,807億円）に達し、同年、医薬品支出は518億4,000万米ドル（396億円）に達しました。さらに、予防医療費は2020年の2倍以上となり、2021年には459億3,000万米ドル（351億ポンド）に達します。したがって、医療費の急増が巣状分節性糸球体硬化症（FSGS）治療薬市場の成長の原動力となっています。

2023年の巣状分節性糸球体硬化症治療薬市場では北米が最大地域でした。巣状分節性糸球体硬化症（FSGS）治療薬レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の巣状分節性糸球体硬化症治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ロスマピモド
  • SHP-627
  • スパルセンタン
  • TM-5484
  • その他のタイプ
  • 世界の巣状分節性糸球体硬化症治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • コルチコステロイド
  • 免疫抑制薬
  • アンジオテンシン変換酵素（ACE）阻害剤
  • ARブロッカー
  • 利尿薬
  • その他の治療
  • 世界の巣状分節性糸球体硬化症治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • 世界の巣状分節性糸球体硬化症治療薬市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • ホームケア
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の巣状分節性糸球体硬化症治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の巣状分節性糸球体硬化症治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 巣状分節性糸球体硬化症治療薬市場の競合情勢
  • 巣状分節性糸球体硬化症治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Ltd.
    • F. Hoffmann-La Roche AG
    • Bayer AG
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Sanofi S.A.
  • Bristol Myers Squibb Company
  • AstraZeneca Plc
  • Fresenius Kabi Ltd.
  • GSK Plc
  • Medtronic Plc.
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Mylan N.V.
  • B. Braun Melsungen AG
  • Hikma Pharmaceuticals PLC
  • Alexion Pharmaceuticals
  • Wockhardt

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12212

“Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on focal segmental glomerulosclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for focal segmental glomerulosclerosis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The focal segmental glomerulosclerosis drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Losmapimod; SHP-627; Sparsentan; TM-5484; Other Types
  • 2) By Treatment: Corticosteroids; Immunosuppressive Drugs; Angiotensin Converting Enzymes (ACE) Inhibitors; A.R. Blockers; Diuretics; Other Treatments
  • 3) By Route of Administration: Oral; Parenteral
  • 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease characterized by the development of scar tissue in the filters of the kidneys. Medications designed to treat and manage the progression of FSGS are referred to as focal segmental glomerulosclerosis drugs.

The primary focal segmental glomerulosclerosis drugs include losmapimod, SHP-627, sparsentan, tm-5484, and others. Losmapimod is an investigational drug belonging to the class of p38 mitogen-activated protein kinase (MAPK) inhibitors. Treatment options encompass corticosteroids, immunosuppressive drugs, ACE inhibitors, AR blockers, diuretics, and more, which can be administered through various routes, including oral and parenteral. These medications serve various end-users, such as hospitals, homecare services, specialty clinics, and more.

The focal segmental glomerulosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides focal segmental glomerulosclerosis drugs market statistics, including focal segmental glomerulosclerosis drugs industry global market size, regional shares, competitors with a focal segmental glomerulosclerosis drugs market share, detailed focal segmental glomerulosclerosis drugs market segments, market trends and opportunities and any further data you may need to thrive in the focal segmental glomerulosclerosis drugs industry. This focal segmental glomerulosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The focal segmental glomerulosclerosis drugs market size has grown strongly in recent years. It will grow from $14.43 billion in 2023 to $15.77 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing disease prevalence, growing demand for new treatments, growing interest from pharmaceutical sector, increasing government support.

The focal segmental glomerulosclerosis drugs market size is expected to see strong growth in the next few years. It will grow to $22.41 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to research and development expenditure, rising healthcare expenditure, growing awareness and diagnosis, aging population, government initiatives and funding. Major trends in the forecast period include technological advancements in drug discovery and development, expanding clinical trials pipeline, improved reimbursement for focal segmental glomerulosclerosis drugs treatments, expansion of corporate research facilities.

The increasing incidence of kidney infections is poised to drive the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market in the foreseeable future. Kidney infections, also known as pyelonephritis, represent a severe form of urinary tract infection (UTI) that affects one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, designed for the treatment of kidney diseases, offer numerous advantages in managing the condition and enhancing kidney function. They achieve this by reducing proteinuria, slowing the progression of kidney damage, and ultimately improving the quality of life for patients suffering from kidney diseases. For example, as of July 2022, data from the Centers for Disease Control and Prevention, a division of the US Department of Health and Human Services, revealed that approximately 15% of the US population, equivalent to 37 million individuals, were afflicted by kidney disease. In 2021, the prevalence was 12% among individuals aged 45-64 and 6% among those between 18 and 44. Consequently, the increasing occurrence of kidney infections serves as a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) market.

The growth of the focal segmental glomerulosclerosis (FSGS) drugs market is expected to be propelled by the increase in healthcare expenditure. Healthcare expenditure encompasses the total amount of money invested in healthcare services and associated products and activities within a specific healthcare system or economy during a specified period. The rising healthcare expenditures play a crucial role in the development and availability of drugs for focal segmental glomerulosclerosis (FSGS). They lead to greater research funding and increased clinical trials, ultimately contributing to improved drug development. For instance, a report from the UK's Office for National Statistics revealed that healthcare spending in the UK saw a 9.4% increase in nominal terms and a 9.7% increase in real terms between 2020 and 2021. The UK's total healthcare expenditure in 2021 amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion) in the same year. Furthermore, preventive care spending more than doubled from 2020, reaching $45.93 billion (£35.1 billion) in 2021. Hence, the surge in healthcare expenditures is a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) drugs market.

The high cost of treatment in the focal segmental glomerulosclerosis (FSGS) market is expected to impede its growth during the forecast period. FSGS is a rare and severe kidney disorder that can ultimately lead to kidney failure. Patients suffering from FSGS often necessitate comprehensive and costly medical care, including hospitalization, dialysis, potential kidney transplantation, intensive care, and specialized diagnostic tests. For instance, the American Hospital Association, a professional organization in the United States, reported a 2.1% increase in hospitalization prices over the year leading up to February 2022. As a result, the substantial expense associated with treatment is acting as a deterrent to the growth of the focal segmental glomerulosclerosis (FSGS) market in the foreseeable future.

Prominent companies in the focal segmental glomerulosclerosis (FSGS) market are increasingly directing their efforts toward product development and innovation to deliver dependable solutions to their clientele and bolster their market standing. As an example, in February 2023, Travere Therapeutics, a biopharmaceutical firm headquartered in the United States, introduced FILSPARI for focal segmental glomerulosclerosis (FSGS), an FDA-approved oral medication. FILSPARI is designed to treat IgA nephropathy (IgAN) and represents the first non-immunosuppressive therapy aimed at reducing proteinuria in IgAN, a rare kidney disease. Furthermore, FILSPARI has received orphan drug designation in both the United States and Europe for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).

In July 2021, AstraZeneca PLC, a pharmaceutical and biotechnology company headquartered in the United Kingdom, completed the acquisition of Alexion Pharmaceuticals for a total of $13.3 billion. This strategic acquisition enhances AstraZeneca's product portfolio, particularly in the manufacturing of drugs tailored for rare diseases that have limited approved treatment options. Additionally, it bolsters their research and development investments across various therapeutic areas, including oncology, cardiology, renal, respiratory, and immunology. Alexion Pharmaceuticals, a pharmaceutical firm based in the United States, specializes in the production of medications for kidney diseases, including focal segmental glomerulosclerosis (FSGS).

Major players in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.

North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2023. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The focal segmental glomerulosclerosis (FSGS) drugs market consists of sales of rituximab, statins, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Focal Segmental Glomerulosclerosis Drugs Market Characteristics

3. Focal Segmental Glomerulosclerosis Drugs Market Trends And Strategies

4. Focal Segmental Glomerulosclerosis Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Focal Segmental Glomerulosclerosis Drugs Market Size and Growth

  • 5.1. Global Focal Segmental Glomerulosclerosis Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Focal Segmental Glomerulosclerosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Focal Segmental Glomerulosclerosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Focal Segmental Glomerulosclerosis Drugs Market Segmentation

  • 6.1. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Losmapimod
  • SHP-627
  • Sparsentan
  • TM-5484
  • Other Types
  • 6.2. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Corticosteroids
  • Immunosuppressive Drugs
  • Angiotensin Converting Enzymes (ACE) Inhibitors
  • A.R. Blockers
  • Diuretics
  • Other Treatments
  • 6.3. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.4. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

7. Focal Segmental Glomerulosclerosis Drugs Market Regional And Country Analysis

  • 7.1. Global Focal Segmental Glomerulosclerosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Focal Segmental Glomerulosclerosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market

  • 8.1. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Focal Segmental Glomerulosclerosis Drugs Market

  • 9.1. China Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 9.2. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Focal Segmental Glomerulosclerosis Drugs Market

  • 10.1. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Focal Segmental Glomerulosclerosis Drugs Market

  • 11.1. Japan Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 11.2. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Focal Segmental Glomerulosclerosis Drugs Market

  • 12.1. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Focal Segmental Glomerulosclerosis Drugs Market

  • 13.1. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Focal Segmental Glomerulosclerosis Drugs Market

  • 14.1. South Korea Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 14.2. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Focal Segmental Glomerulosclerosis Drugs Market

  • 15.1. Western Europe Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 15.2. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Focal Segmental Glomerulosclerosis Drugs Market

  • 16.1. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Focal Segmental Glomerulosclerosis Drugs Market

  • 17.1. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Focal Segmental Glomerulosclerosis Drugs Market

  • 18.1. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Focal Segmental Glomerulosclerosis Drugs Market

  • 19.1. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Focal Segmental Glomerulosclerosis Drugs Market

  • 20.1. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market

  • 21.1. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 21.2. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Focal Segmental Glomerulosclerosis Drugs Market

  • 22.1. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Focal Segmental Glomerulosclerosis Drugs Market

  • 23.1. North America Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 23.2. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Focal Segmental Glomerulosclerosis Drugs Market

  • 24.1. USA Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 24.2. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Focal Segmental Glomerulosclerosis Drugs Market

  • 25.1. Canada Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 25.2. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Focal Segmental Glomerulosclerosis Drugs Market

  • 26.1. South America Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 26.2. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Focal Segmental Glomerulosclerosis Drugs Market

  • 27.1. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Focal Segmental Glomerulosclerosis Drugs Market

  • 28.1. Middle East Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 28.2. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Focal Segmental Glomerulosclerosis Drugs Market

  • 29.1. Africa Focal Segmental Glomerulosclerosis Drugs Market Overview
  • 29.2. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Focal Segmental Glomerulosclerosis Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Focal Segmental Glomerulosclerosis Drugs Market Competitive Landscape
  • 30.2. Focal Segmental Glomerulosclerosis Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Focal Segmental Glomerulosclerosis Drugs Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Bristol Myers Squibb Company
  • 31.3. AstraZeneca Plc
  • 31.4. Fresenius Kabi Ltd.
  • 31.5. GSK Plc
  • 31.6. Medtronic Plc.
  • 31.7. Takeda Pharmaceutical Company Limited
  • 31.8. Eli Lilly and Company
  • 31.9. Astellas Pharma Inc.
  • 31.10. Otsuka Pharmaceutical Co. Ltd.
  • 31.11. Mylan N.V.
  • 31.12. B. Braun Melsungen AG
  • 31.13. Hikma Pharmaceuticals PLC
  • 31.14. Alexion Pharmaceuticals
  • 31.15. Wockhardt

32. Global Focal Segmental Glomerulosclerosis Drugs Market Competitive Benchmarking

33. Global Focal Segmental Glomerulosclerosis Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Focal Segmental Glomerulosclerosis Drugs Market

35. Focal Segmental Glomerulosclerosis Drugs Market Future Outlook and Potential Analysis

  • 35.1 Focal Segmental Glomerulosclerosis Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Focal Segmental Glomerulosclerosis Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Focal Segmental Glomerulosclerosis Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer